Lavipharm Balance Sheet Health
Financial Health criteria checks 4/6
Lavipharm has a total shareholder equity of €51.2M and total debt of €20.1M, which brings its debt-to-equity ratio to 39.2%. Its total assets and total liabilities are €123.5M and €72.3M respectively. Lavipharm's EBIT is €3.6M making its interest coverage ratio 1.8. It has cash and short-term investments of €8.7M.
Key information
39.2%
Debt to equity ratio
€20.07m
Debt
| Interest coverage ratio | 1.8x |
| Cash | €8.69m |
| Equity | €51.18m |
| Total liabilities | €72.34m |
| Total assets | €123.53m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BXA0's short term assets (€47.0M) exceed its short term liabilities (€37.8M).
Long Term Liabilities: BXA0's short term assets (€47.0M) exceed its long term liabilities (€34.5M).
Debt to Equity History and Analysis
Debt Level: BXA0's net debt to equity ratio (22.2%) is considered satisfactory.
Reducing Debt: BXA0 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: BXA0's debt is not well covered by operating cash flow (11.7%).
Interest Coverage: BXA0's interest payments on its debt are not well covered by EBIT (1.8x coverage).